Table 2.

Summary of clinical PsA trials evaluating the efficacy of biologics and apremilast on signs and symptoms of PsO.

Drug	Dosing Regimen	Efficacy (study reference)	Approved for		Efficacy in PsO (per Nast 2012)¹
Drug	Dosing Regimen	Efficacy (study reference)	PsA	PsO	Efficacy in PsO (per Nast 2012)¹
Adalimumab	40 mg SC every other week for 48 weeks	PASI75: 58% after 48 weeks¹⁸	Yes	Yes	PASI75: about 70%
Certolizumab pegol	200 mg every 2 weeks or 400 mg every 4 weeks	PASI75 at week 24: 47%¹⁹	Yes	No	PASI75: 75% (200 mg every other week), 83% (400 mg every other week²⁹)
Etanercept	25 mg SC twice weekly	PASI75 at week 24: 23%²⁰	Yes	Yes	30–70%
Golimumab	50 or 100 mg SC every 4 weeks	PASI75 at week 14: 40% (50 mg); 58% (100 mg)²¹	Yes	No	No published data from PsO trials in the public domain
Infliximab	5 mg/kg IV at weeks 0, 2, 6, 14, and 22	PASI75 at week 14: 64%²²	Yes	Yes	70–90%
Ustekinumab	45 or 90 mg SC at weeks 0, 4, and 16	PASI75 at week 24: 57.2% (45 mg); 62.4% (90 mg)²³	Yes	Yes	About 70%
Abatacept	3, 10, or 30 mg/kg IV at days 1, 15, 19 (except 30 mg group), and then every 4 weeks	PASI75 at day 169: 38% (3 mg), 14% (10 mg), 10% (30 mg)²⁴	No	No	No published data from PsO trials in the public domain
Brodalumab^*	70, 140, or 210 mg SC at day 1 and then at weeks 1, 2, 4, 6, 8, and 10; 280 mg at day 1 and at weeks 4 and 8	PASI75 at week 12: 33% (70 mg), 77% (140 mg), 82% (210 mg), 67% (280 mg)²⁵	No	No	NA
Ixekizumab^*	10, 27, 75, and 150 mg every other week	PASI75 at week 12: 29% (10 mg), 77% (27 mg), 83% (75 mg), 82% (150 mg)²⁷	No	No	NA
Secukinumab^*	75 or 150 mg SC at weeks 0, 4, and 8	PASI75 at week 12: 57% (75 mg), 82% (150 mg)²⁶	No	No	NA
Apremilast	20 or 30 mg orally twice daily for 24 weeks	PASI50 at week 16: 33.8% (20 mg), 50.6% (30 mg)²⁸	Yes	No	PASI75: 24.4% (20 mg twice daily)³⁰

↵* Data for this agent are from PsO clinical trials. PsO: psoriasis; IV: intravenously; PASI: Psoriasis Area and Severity Index; SC: subcutaneously; NA: not applicable.